THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [8.30] ID: TIP-MED-000158

Artemether + Lumefantrine & Artesunate

Active Ingredient / Scientific Identity: Artemether + Lumefantrine & Artesunate • Class: Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022)

⚖️ Compare Profile
Generic / Entity NameArtemether + Lumefantrine & Artesunate ([8.30])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassArtemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (
Available Dosage FormsACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumef
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepati
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Artemether + Lumefantrine & Artesunate (TIP-MED-000158, Reference Code [8.30]) is classified under Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08) as a Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.30], p. 107): Artemether + Lumefantrine (ACT-AL): Falcigo-LF, Coartem (Novartis), Lumax, Lumerax (Ipca). Parenteral Artesunate: Falcigo (Zydus), Larinate (Ipca) — Strengths & Dosage Forms: ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM
Representative Indian Market Examples (Edition 2.7 Ch 08 [8.30], p. 107): Artemether + Lumefantrine (ACT-AL): Falcigo-LF, Coartem (Novartis), Lumax, Lumerax (Ipca). Parenteral Artesunate: Falcigo (Zydus), Larinate (Ipca) — Strengths & Dosage Forms: ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM
Dosage Forms & Available Strengths:
ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022) acting on target receptor/enzyme pathways in Antimicrobials — Antimalarial & Anthelmintic Agents (Ch 08): clinical efficacy is mediated via Artemisinin-Based Combination Therapy (ACT-AL) & Parenteral Severe Malaria Schizonticide (Schedule H | NLEM 2022) for ACT-AL: First-line oral treatment for uncomplicated Plasmodium falciparum malaria (and mixed infections) across India. Parenteral Artesunate: First-line life-saving emergency treatment for Severe / Cerebral Malaria!.

4. Therapeutic Indications & Evidence-Supported Uses

  • ACT-AL: First-line oral treatment for uncomplicated Plasmodium falciparum malaria (and mixed infections) across India
  • Parenteral Artesunate: First-line life-saving emergency treatment for Severe / Cerebral Malaria!

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: ACT-AL Adult (>=35 kg) 6-DOSE, 3-DAY REGIMEN: 80/480 mg (1 Adult Forte tablet, or 4 standard 20/120 mg tablets) at 0 Hours, 8 Hours (on Day 1), then at 24h, 36h, 48h, and 60h (Twice Daily on Days 2 & 3) — Total 6 Doses over 3 Days (+ Single-dose Primaquine 45 mg on Day 2!). Severe Malaria (IV Artesunate): 2.4 mg/kg IV/IM at 0h, 12h, and 24h, then once daily

Administration & Meal Timing: MANDATORY FAT/MILK ABSORPTION RULE FOR LUMEFANTRINE: Every dose of Artemether + Lumefantrine MUST be taken WITH FOOD OR A GLASS OF MILK! Without dietary fat, Lumefantrine oral absorption drops by 90% and malaria treatment fails! | Day 1: Hour 0 & Hour 8; Days 2 & 3: Morning & Evening (12-hourly) WITH MILK OR FOOD

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!
Elimination & Renal Adjustment:
Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!
Hepatic Impairment Considerations:
Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Contraindicated in congenital QTc prolongation, hypokalaemia/hypomagnesaemia, and concomitant strong CYP3A4 inducers (Rifampicin, Carbamazepine, Phenytoin). WHO guidelines endorse Artemether-Lumefantrine across all trimesters of pregnancy!

Key Clinical Precautions: Renal & Hepatic: No dose adjustment needed; in severe malaria with AKI or jaundice, IV Artesunate requires NO renal or hepatic dose reduction!

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Headache, dizziness, anorexia, nausea, arthralgia/myalgia, fatigue, mild QTc prolongation
  • Treatment failure/recrudescence if taken on an empty stomach without fat/milk; Post-Artesunate Delayed Haemolysis (PADH — check Hb at Days 7, 14, 21, & 28 after IV Artesunate!); QTc prolongation
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Strong CYP3A4 Inducers (Rifampicin, Carbamazepine, Phenytoin, Efavirenz) drastically reduce Artemether and Lumefantrine levels -> contraindicated! Avoid QTc-prolonging drugs (Quinine, Macrolides, Fluoroquinolones, Ondansetron, Domperidone)

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: CRITICAL COUNTER INSTRUCTION: Take your second Day-1 dose exactly 8 hours after the first dose, and take all 6 doses over the 3 days WITH A FULL GLASS OF MILK, CURD, OR FOOD — if taken with plain water on an empty stomach, the medicine is not absorbed and falciparum malaria will come back!
  • Meal & Clock Timing Instruction: MANDATORY FAT/MILK ABSORPTION RULE FOR LUMEFANTRINE: Every dose of Artemether + Lumefantrine MUST be taken WITH FOOD OR A GLASS OF MILK! Without dietary fat, Lumefantrine oral absorption drops by 90% and malaria treatment fails! (Day 1: Hour 0 & Hour 8; Days 2 & 3: Morning & Evening (12-hourly) WITH MILK OR FOOD)
  • Missed Dose Protocol: If a dose is vomited within 1 hour, repeat immediately with milk; never skip any of the 6 doses
  • Geriatric Dispensing Pearl: Monitor ECG (QTc) and potassium in older adults

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: ACT-AL Tablets: 20 mg Artemether + 120 mg Lumefantrine; Adult Forte DS Tablet: 80 mg Artemether + 480 mg Lumefantrine. Artesunate Vial: 60 mg, 120 mg for IV/IM

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 08 [8.30] (p. 107)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.